Navigation Links
Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Date:2/5/2008

TF(TM)), designed to upregulate the vascular

endothelial growth factor-A (VEGF-A) gene.

-- Initiation of additional Phase 2 clinical trials of SB-509 in moderate

to severe DN (SB-509-701) and stem cell mobilization (SB-509-703). In

April, Sangamo announced the initiation of a randomized, single-blind,

placebo-controlled, repeat-dosing Phase 2 study designed to evaluate

the clinical safety and effects of repeat administration of SB-509 in

subjects that have moderate to severe DN (SB-509-701). In January

2008, Sangamo announced that it had initiated a randomized,

single-blind, placebo-controlled, multi-center Phase 2 clinical trial

(SB-509-703) in subjects with mild to moderate DN designed to evaluate

the pharmacokinetics of stem cell mobilization into the bloodstream

after treatment with varying doses of SB-509 as well as the clinical

safety and clinical effects of SB-509 administration.

-- Completion of enrollment of Phase 2 clinical trial of SB-509 for mild

to moderate DN (SB-509-601). In December, Sangamo announced that

enrollment was complete in a randomized, double-blind, repeat-dosing,

placebo-controlled, multi-center trial to evaluate SB-509 for the

treatment of mild to moderate DN. The company expects to have data

from this trial in the second half of 2008.

-- Establishment of major alliance with Sigma-Aldrich Corporation. In

July, as part of an agreement to develop and commercialize high value

laboratory research reagents based upon Sangamo's ZFP technology,

Sangamo received an upfront payment of $13.5 million which included

license fees and the purchase of one million shares of Sangamo stock.

Sangamo is also eligible to receive research funding, development and

commercial milestone payments of up to $24 m
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
4. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
5. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
6. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors International ... SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer ... financial results for its first fiscal quarter ended ... Quarter Highlights and Recent Developments: ... improving its cost structure, driven by lower operating ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) ... full year of its fiscal year ended June ... of Array, noted, "Binimetinib and encorafenib, two innovative ... for regulatory submissions in 2016. Additional data shared ... colorectal cancer further validate the value of these ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... , MOUNTAIN VIEW, Calif., ... ) a leading provider of medication system solutions to acute ... (CHS), the largest healthcare system in the Carolinas and third ... OmniRx® automated medication dispensing cabinets (ADCs) to streamline management of ...
... , PISCATAWAY, N.J., Dec. 3 ... recognized leader in advanced injection technologies, today announced that ... National Medicines Corporation Ltd. (d/b/a "Sinopharm") and Yichang Humanwell ... of China (the "PRC"), to develop orthopedic and epidural ...
Cached Medicine Technology:Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 2Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 3Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 4Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Over 400 personnel of the Central Reserve Police Force (CRPF), ... to drugs and alcohol// , according to an internal survey. ... number of men who have become drug dependent and found ... ,He said the survey was started in February ...
... There appears to be no conclusive proof that ... researchers from the American Cancer Society//. This is ... ,Though many medical specialists still prescribe vitamins ... Jacobs, senior epidemiologist and vitamin specialist with the ...
... There is no need for a malaria hospital in Kolkata ... L Joshi, Director of National Vector Born Disease Control Programme. ... dengue and malaria, Joshi said last year in Kolkata only ... the corresponing year was 73., ,Reprentatives of UP, Bihar, ...
... patients who would have to fork out much less ... Merck and Pfizer losing// their patent on drugs commanding ... Ranbaxy and Dr Reddy's Laboratories are being touted as ... vacuum created by the patent expiry of two biggest ...
... for Genetic Engineering and Biotechnology (CIGB) has registered the ... production of an anti-hepatitis B vaccine. // ... a true world scientific breakthrough, and it was obtained ... process required for it. , ,At a press ...
... new study, men with prostate cancer are more influenced ... //from trusting on clinical trial evidences. ... and comparing the anecdotal experiences of others with prostate ... treatment options were entirely different from them are the ...
Cached Medicine News:Health News:Misconception on Treatment Options among Prostate Cancer Patients 2
Ideal for breast compression and contouring breast cups....
Ideal for breast compression with adjustable hook and eye closure....
Female Mini-VEST, Front Closure, X-Firm...
Male Support Brief...
Medicine Products: